SCHEMBL643184

SCHEMBL643184

CC(C)(C)Oc1cccc(OC(C)(C)C)c1CBr

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677746 0.78 KCNH2 (0.39) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL24608079 0.78
SCHEMBL7802337 0.75 CA1 (0.50) KDM4EALDH1A1HSD17B10
SCHEMBL3820431 0.73 CA1 (0.45) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL29428931 0.73 CA1 (0.45) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL30155037 0.72 DPP4 (0.59) KCNH2
SCHEMBL11553756 0.72 KCNH2 (0.43) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL2220781 0.72 KCNH2 (0.43) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL3784828 0.72 KCNH2 (0.43) KCNH2KDM4EALDH1A1HSD17B10
SCHEMBL3817668 0.72 ALDH1A1 (0.46) KCNH2KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119103-B2 Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates MALLINCKRODT LLC (US) 2012-02-21 US disclosed
EP-2065057-A2 Chelating conjugates having a substituted aromatic moiety and derivatives thereof Mallinckrodt Inc. (US) 2009-06-03 EP disclosed
EP-2065057-A2 Chelating conjugates having a substituted aromatic moiety and derivatives thereof Mallinckrodt Inc. (US) 2009-06-03 EP disclosed
US-20090082324-A1 Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates INFACARE PHARMACEUTICAL CORPORATION 2009-03-26 US disclosed
US-20090053137-A1 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof SpecGx LLC 2009-02-26 US disclosed
US-20090053137-A1 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof SpecGx LLC 2009-02-26 US disclosed
US-20090053137-A1 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof SpecGx LLC 2009-02-26 US disclosed
EP-1993613-A2 CHELATING CONJUGATES HAVING A SUBSTITUTED AROMATIC MOIETY AND DERIVATIVES THEREOF Mallinckrodt, Inc. (US) 2008-11-26 EP disclosed
EP-1988925-A2 BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES MALLINCKRODT, INC. (US) 2008-11-12 EP disclosed
WO-2007106544-A2 CHELATING CONJUGATES HAVING A SUBSTITUTED AROMATIC MOIETY AND DERIVATIVES THEREOF MALLINCKRODT INC. (US) 2007-09-20 WO disclosed
WO-2007100563-A2 BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES MALLINCKRODT INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090053137-A1 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof SLC30A5, SLC40A1, SLC46A1 KCNH2 3102/4885KDM4E 2820/4885ALDH1A1 905/4885
US-20090082324-A1 Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates SPR, QDPR, SLC40A1 KCNH2 3052/4885KDM4E 3612/4885ALDH1A1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.